ITI Life Sciences Launches New R&D Program: £5.5 Million To Develop New Predictive Safety Models For Early Drug Development
ITI Life Sciences (Dundee, Scotland), together with CXR Biosciences (Dundee) and Artemis Pharmaceuticals (Cologne, Germany), today announces the launch of a new £5.5 million R&D programme to develop new screening and safety models to more accurately predict the effects of drug compounds and their breakdown products in the human body.